Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes Aumento do estresse oxidativo como um mecanismo para a diminuição dos níveis de BDNF em episódios maníacos agudos 
Introduction
There is an emerging body of evidence suggesting that brainderived neurotrophic factor (BDNF) may play a role in the pathophysiology of bipolar disorder (BD). We recently showed that serum levels of BDNF are decreased during both manic and depressive mood episodes, being normalized in euthymia.
1 These changes in BDNF levels were negatively correlated with the severity of manic and depressive symptoms. Moreover, first-line mood stabilizers, such as lithium and valproate, are known to increase BDNF levels. 2 Despite the reported association of lower levels of serum BDNF with BD morbidity and its reversal by effective treatment, the underlying neurobiological mechanisms of BDNF decrease in acute mood episodes are unknown.
Interestingly, there is evidence showing that oxidative stress may be increased in conditions where BDNF is described to be decreased in BD. For instance, there is evidence of increased oxidative stress, particularly during mood episodes. 3 Moreover, preclinical studies have shown that lithium and valproate exert antioxidant effects in vitro and in vivo. 4, 5 Under situations where oxidative damage reduces cAMP response element binding (CREB) expression, and CREB as well as p-CREB content, oxidative stress is associated with a decrement in BDNF expression and content. 6 To the best of our knowledge, the correlation between oxidative stress and BDNF levels has not been investigated in a clinical sample. In the present study, we have reanalyzed our data on BDNF and oxidative stress 1, 3 and investigated the correlation between serum thiobarbituric acid reactive substances (TBARS -a measure of lipid peroxidation) and serum BDNF levels in BD patients during acute mania and in healthy controls. We hypothesized that there would be a negative correlation between serum TBARS and BDNF levels in manic BD patients, but not in healthy controls.
Method
Detailed demographic and clinical information about the subjects have been described elsewhere.
1, 3 We reanalyzed our data on serum BDNF and TBARS levels using Pearson correlation coefficient, given that BDNF and TBARS values were normally distributed. In brief, 32 manic BD patients were recruited from the Inpatient Psychiatric Unit of the University Hospital (Santa Maria, Brazil). This work was approved by the local ethics committee and all of the subjects provided written informed consent. Patients were interviewed using the Structured Clinical Interview for DSM-IV-Axis I. Thirtytwo healthy controls were matched for age, gender and education. Control subjects were not on medication and had no history of major psychiatric disorders, dementia, mental retardation, and no such disorders were present in their first-degree relatives. Five milliliters of blood were withdrawn from each subject by venipuncture into a freeanticoagulant vacuum tube for biochemical analyses. Serum BDNF levels were measured using a commercial kit of sandwich-ELISA according to the manufacturer's instruction (Chemicon, USA). The standard curve demonstrated a direct relationship between optical density and BDNF concentration. Total protein was measured by Lowry's method using bovine serum albumin as standard. TBARS were measured using the method described by Wills. 3 All assays were performed blind to the subject's status.
Results
In BD patients, there was a significant negative correlation between serum TBARS and BDNF levels (r = -0.56; p = 0.001; Figure 1 ). No significant correlation between serum TBARS and BDNF levels was observed in the control group (r = 0.1; p = 0.61).
Discussion
These results suggest that increased oxidative stress is associated with lower BDNF levels, although a causal relationship cannot be inferred. Several mechanisms by which oxidative stress could decrease BDNF have been suggested, including decreased CREB, increased NF-kB DNA-binding activity 7, 8 or energy depletion. 6 Notably, decreased CREB levels and increased NF-kB gene expression have been found in postmortem brains of BD subjects 9,10 and an energy crisis due to mitochondrial dysfunction has been implicated in the pathophysiology of BD.
11 It should also be mentioned that alterations in the redox status can trigger endoplasmic reticulum stress, which in turn suppresses activitydependent BDNF expression. 12 The present data raise the intriguing possibility that the decrease in BDNF levels in acute affective episodes could be mechanistically related to increased oxidative stress. Correcting the oxidative imbalance in BD may offer a new means of controlling the detrimental effects of mood episodes on cognition and bodily systems, and if it also prevented the associated decrements in BDNF would provide more direct evidence for the hypothesized causal relationship between increased oxidative stress and lower levels of BDNF. As we have previously mentioned, 1,3 medication status may have influenced the present results. Antidepressants are known to increase serum BDNF in humans 13 and data from animal models demonstrate that mood stabilizers can increase cerebral BDNF 14 and regulate cerebral TBARS levels in rodents in vivo. 5 A preliminary case-report suggested that treatment with lithium and antipsychotics may normalize serum TBARS levels in humans, 15 but studies with larger samples are clearly warranted to better determine this issue.
In conclusion, we found that serum TBARS was negatively correlated with serum BDNF levels in manic BD patients, but not in healthy volunteers. These findings suggest that increased oxidative stress may be associated with lower BDNF levels under pathological conditions such as acute mania.
